Том 18 № 4 (2014): Нарушения ритма сердца (спецвыпуск)
ОРИГИНАЛЬНЫЕ СТАТЬИ: НАРУШЕНИЯ РИТМА СЕРДЦА

МОДУЛЯЦИЯ АВТОНОМНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ ДЕНЕРВАЦИИ ПОЧЕЧНЫХ АРТЕРИЙ ДЛЯ ЛЕЧЕНИЯ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ

PDF
  • Д. Заманов,
  • А. Дмитриев,
  • Н. Шильников,
  • Э. Иваницкая,
  • А. Пустовойтов,
  • А. Романов,
  • Е. Покушалов
Д. Заманов
КГБУЗ «Краевая клиническая больница»
Bio
А. Дмитриев
КГБУЗ «Краевая клиническая больница»
Bio
Н. Шильников
КГБУЗ «Краевая клиническая больница»
Bio
Э. Иваницкая
КГБУЗ «Краевая клиническая больница»
Bio
А. Пустовойтов
КГБУЗ «Краевая клиническая больница»
Bio
А. Романов
ФГБУ «ННИИПК им. акад. Е.Н. Мешалкина» Минздрава России
Bio
Е. Покушалов
ФГБУ «ННИИПК им. акад. Е.Н. Мешалкина» Минздрава России
Bio
DOI: https://doi.org/10.21688/1681-3472-2014-4-113-122

Опубликован 28.10.2014

Ключевые слова

  • РЕНАЛЬНАЯ ДЕНЕРВАЦИЯ,
  • ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ,
  • РЕЗИСТЕНТНАЯ ГИПЕРТЕНЗИЯ

Как цитировать

Заманов, Д., Дмитриев, А., Шильников, Н., Иваницкая, Э., Пустовойтов, А., Романов, А., & Покушалов, Е. (2014). МОДУЛЯЦИЯ АВТОНОМНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ ДЕНЕРВАЦИИ ПОЧЕЧНЫХ АРТЕРИЙ ДЛЯ ЛЕЧЕНИЯ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. Патология кровообращения и кардиохирургия, 18(4), 113–122. https://doi.org/10.21688/1681-3472-2014-4-113-122

Copyright (c) 2014 Заманов Д.А., Дмитриев А.Ю., Шильников Н.В., Иваницкая Э.Э., Пустовойтов А.В., Романов А.Б., Покушалов Е.А.

Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.

Аннотация

Автономная нервная система играет ключевую роль в модуляции нормальной электрофизиологии сердца. Несмотря на увеличение количества данных о наличии анатомических и функциональных взаимосвязей между нервной системой и сердцем, остается ряд вопросов [1-11]. Денервация почечных артерий, или ренальная денервация (РД), стала важным интервенционным методом лечения резистентной артериальной гипертензии (АГ). Так как АГ является одним из наиболее распространенных сердечно-сосудистых заболеваний, которое усложняет течение нарушений ритма сердца, особенно фибрилляции предсердий, необходимо исследовать потенциальную ценность РД в качестве антиаритмической терапии.

PDF

Библиографические ссылки

  1. Kapa S., Venkatachalam K.L., Asirvatham Samuel J. The Autonomic Nervous System in Cardiac Electrophysiology: an elegant interaction and emerging concepts. Cardiol. Rev. 2010; 18: 275-84.
  2. Armour J.A., Murphy D.A., Yuan B.X., et al. Gross and microscopic anatomy of the human intrinsic cardiac nervous system. Anat. Rec. 1997; 247: 289-98.
  3. Davies F., Francis E.T., King T.S. Neurological studies of the cardiac ventricles of mammals. J. Anat. 1952; 86: 130-43.
  4. Kuntz A. The Autonomic Nervous System. Philadelphia, PA: Lea & Febiger; 1934.
  5. Janes R.D., Brandys J.C., Hopkins D.A., et al. Anatomy of human extrinsic cardiac nerves and ganglia. Am. J. Cardiol. 1986; 57: 299-309.
  6. Lloyd T.C. Jr. Control of systemic vascular resistance by pulmonary and left heart baroreflexes. Am. J. Physiol. 1972; 222: 1511-17.
  7. Lloyd T.C. Jr., Fried J.J. Effect of a left atrium-pulmonary vein baroreflex on peripheral vascular beds. Am. J. Physiol. 1977; 233: H587-H591.
  8. Edis A.J. Aortic baroreflex function in the dog. Am. J. Physiol. 1971; 221: 1352-57.
  9. Mitchell R.A. Location and function of medullary respiratory neurons. Am. Rev. Respir Dis. 1977; 115: 209-16.
  10. Thoren P.N. Characteristics of left ventricular receptors with nonmedullated vagal afferents in cats. Circ. Res. 1977; 40: 415-21.
  11. Alex Y. Tan, Richard L. Verrier. The role of the autonomic nervous system in cardiac arrhythmias.
  12. Shen M.J., Choi E.K., Tan A.Y., Lin S.F., Fishben M.C., Chen L.S., Chen P.S. Neural mechanisms of atria arrhythmias. Nat. Rev. Cardiol. 2012; 9: 30-9.
  13. Chou C.C., Chen P.S. New concepts in atrial fibrillation: neural mechanisms and calcium dynamics. Cardiol. Clin. 2009; 27: 35-43.
  14. Schauerte P., Scherlag B.J., Patterson E., et al. Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system. J. Cardiovasc. Electrophysiol. 2001; 12: 592-99.
  15. Scherlag B.J., Yamanashi W.S., Patel U., et al. Autonomically induced conversion of pulmonary vein focal firing into atrial fibrillation. J. Am. Coll. Cardiol. 2005; 45: 1878-86.
  16. Nakagawa H., Scherlag B.J., Aoyama H., et al. Catheter ablation of cardiac autonomic nerves for prevention of atrial fibrillation in a caninemodel (Abstract). Heart Rhythm. 2004; 1: S10.
  17. Patterson E., Po S., Scherlag B.J., Lazzara R. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm. 2005; 2: 624-31.
  18. Zhou J., Scherlag B., Ewards J., et al. Gradients of atrial refractoriness and inducibility of atrial fibrillation due to stimulation of ganglionated plexi. J. Cardiovasc. Electrophysiol. 2007; 18: 83-90.
  19. Chevalier P., Tabib A., Meyronnet D., et al. Quantitative study of nerves of the human left atrium. Heart Rhythm. 2005; 2: 518-22.
  20. Linz D., Ukena C., Mahfoud F., Neuberger H., Bhm M., Atrial Autonomic Innervation A Target for Interventional Antiarrhythmic Therapy? J. Am. Coll. Cardiol. 2014; 63 (3): 215-24.
  21. Schlaich M.P., Schmieder R.E., Bakris G., et al. International expert consensus statement: Percutneous transluminal renal denervation for the treatment of resistant hypertension. J. Am. Coll. сardiol. 2013; 62 (22): 2031-45.
  22. Pokushalov E., Romanov A., Corbucci G., Artyomenko S., Baranova V., Turov A., Shirokova N., Karaskov A., Mittal S., Steinberg J.S. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J. Am. Coll. Cardiol. 2012; 60: 1163-70.
  23. Remo B.F., Preminger M., Bradfield J., Mittal S., Boyle N., Gupta A., Shivkumar K., Steinberg J.S., Dickfield T. Safety and efficacy of renal denervation as a novel treatment of ventricular tachycardia storm in patients with cardiomyopathy. Heart Rhythm. 2014; 11: 541 -46.
  24. Huxley R.R., Lopez F.L., Folsom A.R., et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123: 1501-8.
  25. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2011; 123: e269-367.
  26. Katritsis D.G., Toumpoulis I.K., Giazitzoglou E., Korovesis S., Karabinos I., Paxinos G., Zambartas C., Anagnostopoulos C.E. Latent arterial hypertension in apparently lone atrial fibrillation. J. Interv. Card. Electrophysiol. 2005; 13: 203-7.
  27. Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev. 2011; 91: 265-325.
  28. Lau D., Mackenzie L., Kelly D., et al. Hypertension and atrial fibrillation: Evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm. 2010; 7: 1282-90.
  29. Bettoni M., Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation. 2002; 105: 2753-59.
  30. Arimoto T., Tada H., Igarashi M., Sekiguchi Y., Sato A., Koyama T., Yamasaki H., Machino T., Kuroki K., Kuga K., Aonuma K. High washout rate of iodine-123-metaiodobenzylguanidine imaging predicts the outcome of catheter ablation of atrial fibrillation. J. Cardiovasc Electrophysiol. 2011; 22: 1297-304.
  31. Katritsis D., Pokushalov E., Romanov A., Giazitzoglou E., Siontis G.C., Po S.S., Camm A.J., Ioannidis J.P. Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial. J. Am. Coll. Cardiol. 2013; 735-1097.
  32. Pokushalov E. The role of autonomic denervation during catheter ablation of atrial fibrillation. Curr. Opin. Cardiol. 2008; 23 (1): 55-9.
  33. Stella A.and Zanchetti A. Functional role of renal afferents. Physiol. Rev. 1991; 71: 659-82.
  34. DiBona G.F. and Kopp U.C. Neural control of renal function. Physiol Rev. 1997; 77: 75-197.
  35. Ye S., Ozgur B., Campese V.M. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997; 51: 722-27.
  36. Kumagai K., Nakashima H., Urata H., et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 2003; 41: 2197-2204.
  37. Nakashima H., Kumagai K., Urata H., et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000; 101: 2612-17.
  38. Berkowitsch A., Neumann T., Kuniss M., et al. Therapy with reninangiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder? PACE. 2010; 33: 1101-11. Контекст: ...РААС участвует в образовании миокардиального фиброза и увеличении выброса ангиотензина II, вызывая выраженную дилатацию предсердия с локальным фиброзом и развитие ФП [38].
  39. Healy J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 2005; 45: 1832-39.
  40. GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N. Eng. J. Med. 2009; 360: 1606-17.
  41. Schlaich M.P., Kaye D.M., Lambert E., et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560-65.
  42. Burns J., Sivananthan M.U., Ball S.G., et al. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007; 115: 1999-2005.
  43. Kaye D.M., Lambert G.W., Lefkovits J., et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J. Am. Coll. Cardiol. 1994; 23: 570-78.
  44. Kaye D.M., Lefkovits J., Jennings G.L., et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol. 1995; 26: 1257-63.
  45. Yang S.S., Han W., Cao Y., et al. Effects of high thoracic epidural anesthesia on atrial electrophysiological characteristics and sympathetic nerve sprouting in a canine model of atrial fibrillation. Basic. Res. Cardiol. 2011; 106: 495-506.
  46. Tan A.Y., Zhou S., Ogawa M., et al. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation. 2008; 118: 916-25.
  47. Sobotka P.A., Mahfoud F., Schlaich M.P., et al. Sympatho-renal axis in chronic disease. Clin. Res. Cardiol. 2011; 100: 1049-57.
  48. Schlaich M.P., Sobotka P.A., Krum H., Lambert E., Esler M.D. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Eng. J. Med. 2009; 361: 932-34.
  49. Patterson E., Po S.S., Scherlag B.J., Lazzara R. Triggered firing of pulmonary veins by in vitro autonomic nerve stimulation. Heart Rhythm. 2005; 2: 624-31.
  50. Lau D.H., Mackenzie L., Kelly D.J., et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm. 2010; 7: 1282-90.
  51. Linz D., Mahfoud F., Schotten U., et al. Renal sympathetic denervation provide ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension. 2013; 61: 225-31.
  52. Zhao Q., Yu S., Zou M., et al. Effects of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing. JICE. 2012; 35: 119-25.
  53. Linz D., Mahfoud F., Schotten U., et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 2012; 60: 172-8.
  54. Kline R.L. and Mercer P.F. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am. J. Physiol. 1980; 238: R353-R8.
  55. Arrowood J.A., Goureau J.A., Minisi A.J., Davis A.B., Mohanty P.K. Evidence against reinnervation of cardiac vagal afferents after human orthotopic cardiac transplantation. Circulation. 1995; 92: 402-8.
  56. Pokushalov E., Romanov A., Katritsis D.G., Artyomenko S., Bayramova S., Losik D., Baranova V., Karaskov A., Steinberg J.S. Renal denervation for improving outcomes of catheter ablation in patients with atrial fibrillation and hypertension: Early experience. Heart Rhythm. 2014; 11 (7): 1131-8.
  57. Huxley R.R., Lopez F.L., Folsom A.R., et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123: 1501-8.
  58. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2011; 123: e269-367.
  59. Ott C., Mahfoud F., Schmid A., Ditting T., Sobotka P.A., Veelken R., Spies A., Ukena C., Laufs U., Uder M., Bhm M., Schmieder R.E. Renal denervation in moderate treatment resistant hypertension. J. Am. Coll. Cardiol. 2013; 62 (20): 1880-6.
  60. Bhatt D.L., Kandzari D.E., ONeill W.W., DAgostino R., Flack J.M., Katzen B.T., Leon M.B., Liu M., Mauri L., Negoita M., Cohen S.A., Oparil S.,Rocha-Singh K., Townsend R.R., Bakris G.L. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014 Apr 10; 370 (15): 1393-401.
  61. Norvell J.E. The aorticorenal ganglion and its role in renal innervation. J. Comp. Neur. 1968; 133: 101-12.
  62. Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560-72.
  63. Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-87.
  64. Krum H., Schlaich M., Whitbourn R., Sobotka P.A., Sadowski J., Bartus K., Kapelak B., Walton A., Sievert H., Thambar S., Abraham W.T., Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 11373 (9671): 1275-81.

Похожие статьи

Вы также можете начать расширеннвй поиск похожих статей для этой статьи.